Skip to Content

Symproic Approval History

FDA Approved: Yes (First approved March 23, 2017)
Brand name: Symproic
Generic name: naldemedine
Dosage form: Tablets
Company: Shionogi Inc.
Treatment for: Opioid-Induced Constipation

Symproic (naldemedine) is a peripherally-acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation.

Development History and FDA Approval Process for Symproic

DateArticle
Mar 23, 2017Approval FDA Approves Symproic (naldemedine) for the Treatment of Opioid-Induced Constipation
Jun  6, 2016Shionogi Announces Acceptance of NDA for Naldemedine for the Treatment of Opioid-Induced Constipation
Mar 30, 2016Shionogi Submits New Drug Applications in Japan and the U.S. for Naldemedine for the Treatment of Opioid-Induced Constipation

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide